Recombinant Yersinia pseudotuberculosis serotype IB Urocanate hydratase (hutU), partial

What is the function of Urocanate hydratase (hutU) in Yersinia pseudotuberculosis?

Urocanate hydratase (hutU) in Y. pseudotuberculosis is an enzyme that catalyzes the conversion of urocanate to 4-imidazolone-5-propionate as part of the histidine degradation pathway. This pathway is essential for bacterial nitrogen metabolism and can be critical during certain stages of infection or when histidine is a primary nitrogen source. The enzyme belongs to the urocanase family and plays a role in the bacterium's metabolic versatility, potentially contributing to its ability to survive in diverse environments including during infection of mammalian hosts. Understanding hutU's metabolic role provides insight into Y. pseudotuberculosis' adaptation strategies during colonization of lymphoid tissues and internal organs such as the liver, where the bacterium can cause significant pathology .

How do I design primers for amplifying the hutU gene from Y. pseudotuberculosis serotype IB?

When designing primers for hutU amplification from Y. pseudotuberculosis serotype IB, follow these methodological steps:

• Obtain the complete hutU gene sequence from genome databases specific to Y. pseudotuberculosis serotype IB.

• Design forward and reverse primers (20-25 nucleotides) with similar melting temperatures (Tm within 5°C of each other).

• Include restriction enzyme sites at the 5' ends with additional 3-6 nucleotides upstream of the restriction sites to ensure efficient enzyme cutting.

• Consider the expression vector you will use, ensuring the reading frame will be maintained and appropriate tags can be added.

• Check primers for potential self-complementarity, hairpin formation, and non-specific binding to other regions of the Y. pseudotuberculosis genome.

• Include a high-fidelity DNA polymerase in your PCR protocol to minimize mutations, especially important for enzyme expression where a single amino acid change could affect catalytic activity.

This approach is similar to strategies used for cloning other Y. pseudotuberculosis genes, as demonstrated in recombinant attenuated strain development .

What expression systems are most suitable for recombinant hutU production?

The selection of an appropriate expression system for recombinant hutU production depends on your specific experimental needs:

E. coli-based systems:

• BL21(DE3) strains are typically preferred for hutU expression due to their reduced protease activity and tight control of T7 promoter systems.

• Consider using pET vector systems with IPTG-inducible promoters for high-level expression.

• The addition of a His-tag facilitates purification via nickel affinity chromatography, similar to approaches used for other recombinant proteins .

Y. pseudotuberculosis-based systems:

• For native-like expression, consider an attenuated Y. pseudotuberculosis expression system.

• Strains with Δasd mutations (like those described for vaccine development) can provide balanced attenuation while maintaining protein expression capabilities .

• The Type III Secretion System (T3SS) can be leveraged for protein secretion at 37°C under calcium-deprived conditions, which may be advantageous for certain experimental designs .

The choice between these systems should be guided by whether native conformation/post-translational modifications are required or if high yield is the primary consideration.

What are the optimal conditions for inducing hutU expression in recombinant systems?

Optimization of hutU expression requires careful consideration of multiple parameters:

Temperature:

• Lower induction temperatures (16-25°C) often yield higher amounts of soluble hutU protein by slowing protein folding and preventing inclusion body formation.

• Conduct expression tests at 37°C, 30°C, 25°C, and 18°C to determine the optimal temperature.

Induction timing and concentration:

• For IPTG-inducible systems, induction at mid-log phase (OD600 of 0.6-0.8) typically yields better results than early or late growth phases.

• Test IPTG concentrations ranging from 0.1 mM to 1.0 mM, as lower concentrations may improve soluble protein yield.

Media composition:

• Enriched media (e.g., TB or 2YT) often produce higher cell densities and protein yields compared to standard LB medium.

• For expressing selenomethionine-labeled hutU (for crystallography studies), use minimal media with controlled methionine sources.

Duration:

• Extended expression periods (16-24 hours) at lower temperatures may increase yields of properly folded protein.

This methodological approach is consistent with techniques used for other recombinant proteins from Yersinia species, focusing on balancing expression levels with proper protein folding to maintain enzymatic activity .

How can I optimize the purification protocol for recombinant hutU protein?

A comprehensive purification strategy for recombinant hutU should include:

Initial clarification:

• Cell lysis using sonication or high-pressure homogenization in buffer containing 50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10% glycerol, and protease inhibitors.

• Centrifugation at 20,000 × g for 30 minutes to remove cell debris.

Affinity chromatography:

• For His-tagged hutU, use Ni-NTA resin with an imidazole gradient (20-250 mM) for elution.

• Consider on-column refolding if the protein is predominantly in inclusion bodies.

Secondary purification:

• Ion-exchange chromatography (typically Q-Sepharose) can separate hutU from contaminants with different charge properties.

• Size-exclusion chromatography as a polishing step to remove aggregates and ensure monodispersity.

Quality assessment:

• SDS-PAGE analysis to verify purity (aim for >90% as determined by Bis-Tris PAGE) .

• Western blot to confirm identity.

• Analytical SEC (HPLC) to assess homogeneity and oligomeric state.

Buffer optimization:

• Test thermal stability in different buffers using differential scanning fluorimetry.

• Include stabilizing agents (e.g., glycerol 5-10%) in the final storage buffer.

• Determine protein concentration using Bradford or BCA assays calibrated with BSA standards.

Store purified hutU at -80°C in small aliquots to avoid repeated freeze-thaw cycles. This protocol incorporates standard approaches for recombinant protein purification while addressing specific considerations for maintaining hutU enzymatic activity .

What are the common challenges in obtaining soluble recombinant hutU and how can they be addressed?

Researchers frequently encounter several challenges when expressing recombinant hutU:

Inclusion body formation:

• Challenge: hutU may form insoluble aggregates, particularly at high expression levels.

• Solution: Reduce induction temperature to 18-20°C, lower inducer concentration, or co-express with chaperones (GroEL/GroES, DnaK/DnaJ).

• Methodology: If inclusion bodies persist, develop a refolding protocol using gradual dialysis from denaturing conditions (8M urea or 6M guanidine-HCl) to native buffer.

Proteolytic degradation:

• Challenge: Recombinant hutU may be susceptible to proteolytic cleavage.

• Solution: Include protease inhibitors in all buffers, use protease-deficient expression strains, and maintain samples at 4°C during purification.

• Methodology: Analyze degradation patterns by western blot to identify cleavage sites, then potentially redesign constructs to improve stability.

Low enzymatic activity:

• Challenge: Purified protein may show reduced catalytic efficiency.

• Solution: Test different buffer conditions (pH range 6.5-8.5), add cofactors if required, and ensure proper metal content (if hutU is a metalloenzyme).

• Methodology: Develop a robust activity assay to monitor enzymatic function throughout purification, allowing optimization of conditions that preserve catalytic activity.

Protein aggregation:

• Challenge: hutU may aggregate during concentration or storage.

• Solution: Include stabilizing agents (glycerol, low concentrations of reducing agents), optimize buffer ionic strength, and use size-exclusion chromatography as a final purification step.

• Methodology: Monitor aggregation using dynamic light scattering and optimize storage conditions to maintain monodispersity.

These approaches mirror strategies employed for other recombinant proteins from Yersinia species, where maintaining native conformation is critical for functional studies .

What assays can be used to measure hutU enzymatic activity?

Several complementary assays can be employed to comprehensively characterize hutU enzymatic activity:

Spectrophotometric assay:

• Principle: Urocanate has an absorption maximum at 277 nm that decreases during conversion to imidazolonepropionate.

• Methodology: Monitor the decrease in absorbance at 277 nm in real-time at room temperature in a buffer containing 50 mM potassium phosphate (pH 7.5).

• Analysis: Calculate initial reaction rates at varying substrate concentrations to determine kinetic parameters (Km, Vmax, kcat).

Coupled enzyme assay:

• Principle: Link hutU activity to a secondary reaction that generates a detectable product.

• Methodology: Couple the production of imidazolonepropionate to a downstream enzyme that produces NAD(P)H, which can be monitored at 340 nm.

• Advantage: Increased sensitivity compared to direct measurement.

HPLC-based assay:

• Principle: Separate substrate and product by reversed-phase HPLC.

• Methodology: Quench reactions at various time points, remove protein by filtration, and analyze the reaction mixture by HPLC.

• Advantage: Direct quantification of both substrate depletion and product formation.

Mass spectrometry:

• Principle: Direct detection of substrate and product masses.

• Methodology: Use LC-MS to monitor reaction progress, particularly useful for confirming product identity.

• Advantage: High specificity and ability to detect unexpected reaction products.

Each assay should be validated with appropriate controls, including heat-inactivated enzyme and reactions without substrate. This multi-method approach ensures robust characterization of hutU catalytic properties, following standard enzymological practices for characterizing bacterial metabolic enzymes .

How does the recombinant hutU activity compare with native enzyme from Y. pseudotuberculosis?

When comparing recombinant and native hutU activity, researchers should consider the following methodological approaches:

Extraction of native enzyme:

• Isolate native hutU from Y. pseudotuberculosis grown under conditions that induce histidine utilization pathways.

• Purify using a combination of ammonium sulfate precipitation, ion exchange, and size exclusion chromatography.

• Verify identity by mass spectrometry or N-terminal sequencing.

Comparative activity analysis:

• Subject both enzyme preparations to identical activity assays under standardized conditions.

• Determine and compare kinetic parameters (Km, kcat, kcat/Km) for both preparations.

• Analyze substrate specificity by testing structural analogs of urocanate.

Stability comparison:

• Assess thermal stability using differential scanning fluorimetry.

• Determine pH tolerance profiles by measuring activity across a pH range (5.0-9.0).

• Evaluate storage stability at 4°C and -20°C over defined time periods.

Structural comparison:

• Analyze secondary structure content using circular dichroism spectroscopy.

• Compare oligomeric states using analytical size exclusion chromatography.

• If possible, determine and compare three-dimensional structures.

Typically, recombinant hutU shows 70-90% of native enzyme activity if properly expressed and purified. Differences may arise from incomplete folding, lack of post-translational modifications, or effects of affinity tags. To minimize these differences, consider removing affinity tags after purification using specific proteases (e.g., TEV protease for His-tags) and refolding protocols if necessary to achieve native-like activity .

What role does hutU play in Y. pseudotuberculosis pathogenicity?

The connection between hutU and Y. pseudotuberculosis pathogenicity involves several potential mechanisms:

Nutrient acquisition during infection:

• hutU enables the utilization of histidine as a carbon and nitrogen source in nutrient-limited host environments.

• This metabolic versatility may contribute to Y. pseudotuberculosis' ability to persist in lymphoid tissues and organs like the liver where histidine may be available.

• Similar to other metabolic enzymes, hutU may help the bacterium adapt to changing nutrient landscapes encountered during different stages of infection .

Potential immunomodulatory effects:

• While not directly demonstrated for hutU, bacterial metabolic enzymes can sometimes have secondary functions affecting host immunity.

• The products of histidine metabolism may influence local pH or interact with host signaling pathways.

• Research methodologies: Comparative infection studies with wild-type and hutU knockout strains can elucidate its contribution to virulence.

Association with virulence factors:

• Investigate whether hutU expression is co-regulated with known virulence factors like those encoded by the high-pathogenicity island (HPI).

• Transcriptomic analysis during infection can reveal whether hutU is upregulated concurrently with virulence genes .

Potential as a virulence marker:

• Serotype IB strains of Y. pseudotuberculosis have distinct virulence profiles; investigating hutU sequence variations across serotypes may reveal correlations with pathogenicity.

• PCR-based strain typing focusing on the hutU gene could potentially distinguish between strains with different virulence potentials .

While hutU's primary function is metabolic rather than directly pathogenic, its contribution to bacterial fitness during infection makes it relevant to understanding the comprehensive picture of Y. pseudotuberculosis pathogenesis, particularly in severe infections like Far East scarlet-like fever where liver pathology is common .

How can recombinant hutU be used to develop serotype-specific detection methods for Y. pseudotuberculosis?

Recombinant hutU can be leveraged for developing serotype-specific detection methods through several strategic approaches:

Antibody-based detection systems:

• Methodology: Use purified recombinant hutU to generate polyclonal or monoclonal antibodies specific to serotype IB variants.

• Application: Develop ELISA, lateral flow immunoassays, or immunofluorescence tests for rapid detection.

• Validation: Test antibody specificity against hutU proteins from different Y. pseudotuberculosis serotypes and related Yersinia species.

PCR-based detection:

• Methodology: Identify serotype-specific nucleotide variations in the hutU gene across Y. pseudotuberculosis isolates.

• Design primers targeting these variable regions for conventional or real-time PCR.

• Develop multiplex PCR assays combining hutU detection with other serotype markers.

• Validation: Test assay sensitivity and specificity using a diverse collection of clinical and environmental isolates.

Biosensor development:

• Methodology: Immobilize anti-hutU antibodies or aptamers on biosensor surfaces.

• Monitor binding events through electrochemical, optical, or piezoelectric signal generation.

• Application: Field-deployable devices for environmental or clinical sample testing.

Mass spectrometry-based typing:

• Methodology: Identify serotype-specific peptide markers from tryptic digests of hutU.

• Develop targeted mass spectrometry methods (SRM/MRM) for these peptides.

• Application: High-throughput screening of clinical isolates with minimal sample preparation.

The development of these methods requires careful validation against a panel of Y. pseudotuberculosis isolates from different serotypes, particularly focusing on discriminating serotype IB from closely related variants. This approach is particularly valuable for epidemiological studies tracking the spread of highly pathogenic strains associated with severe manifestations like liver pathology .

How can hutU be incorporated into recombinant vaccine development against Y. pseudotuberculosis?

Incorporating hutU into recombinant vaccine strategies against Y. pseudotuberculosis requires systematic methodological approaches:

As a vaccine antigen:

• Express hutU or immunogenic epitopes as fusion proteins with known immunostimulatory carriers.

• Consider YopE fusion constructs similar to the YopE Nt138-LcrV fusion described in the search results, which has shown strong immunogenicity .

• Methodology: Identify highly conserved regions of hutU that are exposed to the immune system and likely to generate protective responses.

As part of attenuated live vaccines:

• Create recombinant attenuated strains with regulated hutU expression.

• Methodology: Engineer strains with Δyopk ΔyopJ Δasd triple mutations (similar to χ10069) that balance attenuation with strong immunogenic properties .

• Incorporate controlled expression systems for hutU to potentially enhance strain-specific immunity.

For mucosal immunity development:

• Design oral vaccination strategies using attenuated strains expressing hutU.

• Methodology: Test different administration routes (oral, intranasal) and dosing schedules to optimize mucosal IgA production in addition to systemic immunity .

• Evaluate protection against challenge with virulent Y. pseudotuberculosis strains.

Immune response assessment:

• Measure serum antibody titers using standardized ELISAs with purified recombinant hutU.

• Analyze secretory IgA in bronchoalveolar lavage (BAL) fluid to assess mucosal immunity.

• Quantify Y. pseudotuberculosis-specific CD4+ and CD8+ T cells producing cytokines (TNF-α, IFN-γ, IL-2, IL-17) .

• Challenge studies to evaluate protective efficacy against different routes of infection.

This approach leverages successful strategies used with other Y. pseudotuberculosis antigens, where attenuated strains induce comprehensive Th1- and Th2-mediated immune responses and protection against multiple Yersinia species, indicating potential for cross-protection .

What is the potential of hutU as a drug target for treating Y. pseudotuberculosis infections?

Evaluating hutU as a potential drug target requires systematic assessment of several critical factors:

Target validation methodology:

• Generate conditional or complete hutU knockouts in Y. pseudotuberculosis and assess:

  • Growth rates in various media, particularly with histidine as the sole nitrogen source

  • Virulence in cellular and animal infection models

  • Persistence in host tissues, especially liver and lymphoid organs

• Complementation studies to confirm phenotypic changes are specifically due to hutU loss

Assay development for inhibitor screening:

• Establish high-throughput enzymatic assays using purified recombinant hutU

• Develop cell-based secondary assays to evaluate compound penetration and efficacy

• Implement counter-screens against human urocanase (UROC1) to identify selective inhibitors

Structure-based drug design approaches:

• Determine the three-dimensional structure of hutU through X-ray crystallography or cryo-EM

• Identify catalytic residues and potential allosteric sites through mutational analysis

• Perform in silico screening of compound libraries against identified binding pockets

• Validate computational hits using biochemical and biophysical assays

Essential considerations for hutU as a drug target:

• Assess conservation across Yersinia species to determine spectrum of potential activity

• Evaluate essentiality in different infection stages and microenvironments

• Determine if redundant metabolic pathways could circumvent hutU inhibition

• Test potential for resistance development through directed evolution studies

The potential of hutU as a drug target is enhanced if it can be shown to be:

• Essential for in vivo growth or pathogenicity

• Sufficiently different from human UROC1 to allow selective targeting

• Accessible to small molecule inhibitors

• Non-redundant in critical infection stages

This target validation approach follows established drug discovery methodologies while addressing the specific metabolic role of hutU in bacterial pathogenesis during liver and lymphoid tissue infections .

What are the technical challenges in resolving the crystal structure of recombinant hutU?

Crystallizing recombinant hutU presents several technical challenges that require specific methodological solutions:

Protein heterogeneity issues:

• Challenge: Conformational flexibility or post-translational modifications may create sample heterogeneity, hindering crystal formation.

• Methodology: Employ limited proteolysis to identify stable domains, use size-exclusion chromatography to ensure monodispersity (>90% as determined by analytical SEC) , and optimize buffer conditions through thermal shift assays.

• Advanced approach: Surface entropy reduction through strategic mutation of flexible, solvent-exposed lysine and glutamate residues to alanine.

Crystallization optimization:

• Challenge: Initial crystallization hits often produce small or poorly diffracting crystals.

• Methodology: Implement systematic grid screens around initial conditions, varying precipitant concentration, pH, temperature, and protein concentration.

• Advanced techniques: Employ seeding approaches, including microseed matrix screening and streak seeding from initial crystals to improve crystal size and quality.

Phase determination challenges:

• Challenge: Obtaining phase information for structure solution.

• Methodology: Express selenomethionine-labeled hutU for MAD/SAD phasing, or prepare heavy atom derivatives.

• Alternative approach: Molecular replacement using structures of urocanate hydratases from related organisms, though this may be complicated by potential structural differences.

Diffraction quality improvement:

• Challenge: Poor diffraction resolution limiting structural details.

• Methodology: Post-crystallization treatments including dehydration, annealing, and cryoprotectant optimization.

• Advanced approach: Crystal manipulation techniques such as crystal trimming or controlled humidity adjustment using specialized equipment.

Functional state capture:

• Challenge: Capturing functionally relevant conformations.

• Methodology: Co-crystallization with substrates, products, or inhibitors to trap different enzymatic states.

• Time-resolved crystallography to capture reaction intermediates if facilities permit.

These challenges require iterative optimization and often benefit from integrating complementary structural techniques such as small-angle X-ray scattering (SAXS) or cryo-electron microscopy to guide crystallization strategies or provide alternative structural insights .

How can isotope labeling of recombinant hutU contribute to understanding its metabolic role during infection?

Isotope labeling of recombinant hutU provides powerful approaches for tracking and understanding its metabolic functions during Y. pseudotuberculosis infection:

Metabolic flux analysis using 13C-labeled histidine:

• Methodology: Infect cell cultures or animal models with Y. pseudotuberculosis in the presence of 13C-labeled histidine.

• Track the incorporation of labeled carbon into metabolic intermediates using LC-MS/MS.

• Compare wild-type and hutU mutant strains to determine the specific contribution of hutU to histidine utilization during infection.

• Analysis: Construct metabolic flux maps showing how histidine carbon is distributed through central metabolism under different infection conditions.

Protein turnover studies with 15N-labeled hutU:

• Methodology: Express recombinant hutU with 15N incorporation and introduce it into infection models.

• Monitor protein stability and turnover rates in different tissues and infection stages.

• Techniques: Combine with immunoprecipitation and mass spectrometry to track labeled hutU fate in complex biological samples.

• Analysis: Determine half-life and degradation patterns to understand temporal aspects of hutU function.

Interaction studies using SILAC approaches:

• Methodology: Express hutU in heavy isotope-labeled bacterial cultures and identify protein interaction partners during infection.

• Techniques: Cross-linking mass spectrometry to capture transient interactions.

• Differential interactome analysis between standard laboratory conditions and infection-mimicking conditions.

• Analysis: Construct protein interaction networks specific to infection states.

In vivo localization using deuterated hutU:

• Methodology: Express deuterated hutU for neutron scattering studies.

• Techniques: Neutron contrast variation to distinguish labeled hutU from unlabeled host proteins.

• Analysis: Determine subcellular localization and potential membrane associations during different infection phases.

These isotope labeling approaches provide dynamic information beyond static expression levels, revealing how hutU contributes to metabolic adaptation during the establishment of infection in lymphoid tissues and liver, where Y. pseudotuberculosis causes significant pathology .

How do single nucleotide polymorphisms (SNPs) in the hutU gene correlate with virulence differences among Y. pseudotuberculosis strains?

Investigating correlations between hutU SNPs and virulence requires a comprehensive methodological approach:

Comparative genomic analysis:

• Methodology: Sequence the hutU gene from diverse Y. pseudotuberculosis isolates, particularly comparing strains from different geographic origins and disease presentations.

• Pay special attention to strains associated with Far East scarlet-like fever (FESLF), which shows enhanced liver pathology .

• Bioinformatic analysis: Identify non-synonymous SNPs and map them to functional domains of the hutU protein.

• Phylogenetic analysis to determine if certain hutU variants cluster with specific lineages known for enhanced virulence.

Structure-function correlation:

• Methodology: Model the impact of identified SNPs on protein structure using computational approaches.

• Express and purify recombinant hutU variants carrying different naturally occurring SNPs.

• Compare enzymatic parameters (Km, kcat, substrate specificity) between variants.

• Assess thermal stability and pH optima to determine if SNPs affect enzyme robustness under stress conditions.

Virulence assessment:

• Methodology: Generate isogenic Y. pseudotuberculosis strains differing only in hutU variants.

• Compare virulence in cellular infection models and animal models.

• Assess bacterial loads in lymphoid tissues and liver, histopathological changes, and inflammatory markers.

• Measure competitive fitness of different hutU variants during co-infection experiments.

Gene expression analysis:

• Methodology: Determine if hutU SNPs affect gene expression levels or patterns.

• Perform RT-qPCR to measure hutU expression levels under different conditions.

• Investigate if certain SNPs create or disrupt regulatory element binding sites.

• Use reporter constructs to visualize expression patterns in different host microenvironments.

This systematic approach can reveal whether hutU variation contributes to the spectrum of disease manifestations observed with Y. pseudotuberculosis infections, particularly the severe liver pathology observed in FESLF cases, where liver damage is detected in 50% of infected individuals .